The Screen That Matters More Than the Dose
Most psychedelic safety content focuses on what you take, how much, and where. But the single most consequential variable in psychedelic safety isn't pharmacological — it's who you are. A substance that is statistically gentle for most people can be catastrophic for a specific minority, and the difference isn't preference, karma, or preparation. It's biology: personal and family histories that place certain brains on the wrong side of a line that clinical researchers draw early and enforce absolutely, because the trials taught them what happens when it's ignored. This post is about that line — who shouldn't use classic psychedelics, why the contraindications are non-negotiable, and what "respecting the molecule" actually means when your own history puts you in its crosshairs.
The Crown Jewel of Contraindications: Psychosis Risk
Everything in this category funnels through one mechanism. Classic psychedelics amplify the brain's existing signal processing — that's their entire pharmacology — and in a nervous system with latent vulnerability to psychosis, amplification can flip a switch that doesn't flip back. The evidence base is sobering and consistent:
Personal history of psychosis. Anyone who has experienced a psychotic episode — schizophrenia, schizoaffective disorder, a psychotic-featured bipolar episode, even a single drug-induced psychosis that resolved — faces a markedly elevated risk of psychedelic-precipitated recurrence. Clinical trials exclude these participants absolutely, not from abundance of caution but from documented experience.
Family history of schizophrenia or psychotic disorders. First-degree relatives of people with schizophrenia carry substantially elevated lifetime psychosis risk — and psychedelics may lower the threshold for its expression. A person can have no symptoms whatsoever and still carry the loading; the trip is a stress test the family history says not to run. Every serious screening protocol asks about family history, and it belongs in every personal decision too.
Prodromal symptoms. The subtle early warnings of emerging psychotic illness — attenuated hallucinations, growing paranoia, disorganized thinking that comes and goes, a creeping sense of external influence — are exactly the material a large serotonergic dose will blast into full presentation. If you or someone close to you has noticed these changes, the psychedelic question is closed until a psychiatrist has evaluated them.
The honest framing of the magnitude: psychedelics don't cause schizophrenia in the way a germ causes infection — the illness has roots in genetics and development that predate any drug. But they can function as the trigger in a loaded system, and triggering an episode earlier, or more severely, or in someone whose resilience might have held the illness off, is a harm of a completely different order than a difficult night.
Bipolar Disorder: A Second Absolute
Bipolar disorder earns its own entry because its risk profile with psychedelics is distinct and serious. Serotonergic stimulation is destabilizing to the bipolar brain's mood regulation in both directions: manic or hypomanic activation is the acute danger (documented cases include severe, prolonged manic episodes with psychotic features following psychedelic use, sometimes requiring hospitalization), and depressive destabilization follows for some. The current clinical consensus treats bipolar disorder — particularly bipolar I, and any history of manic episodes — as a contraindication to serotonergic psychedelics in non-supervised settings, and even the most progressive research protocols approach it with extreme caution. The bipolar-diagnosed person drawn to psychedelic healing has legitimate company — ketamine research and some psychedelic-adjacent protocols are actively exploring bipolar depression — but exploration belongs in clinical hands, never solo.
Cardiovascular Exclusions
The heart-focused post in this series covers the pharmacology; the screening version is simple. Uncontrolled hypertension, significant coronary artery disease, history of stroke, clinically significant arrhythmias, and severe valvular disease place a person outside the safety envelope of an experience that deliberately raises blood pressure and heart rate for hours. The exclusions are dose-independent — a gentle 10mg psilocybin session stresses the cardiovascular system the same direction as a stronger one — and age amplifies all of it. Anyone over roughly 50 with cardiac risk factors owes themselves a physician conversation before any session, not after the first chest flutter at peak.
The Medication Walls
Two categories are absolute, as covered in this series' interaction posts:
MAOIs, in either direction, with any serotonergic psychedelic — the serotonin syndrome risk is real, mechanistically solid, and occasionally fatal. This includes the harmala alkaloids of ayahuasca, which make the brew itself an MAOI and multiply every interaction in the category.
Lithium deserves a special, under-known entry: conventional psychiatric teaching holds that lithium plus LSD or other serotonergic psychedelics carries a seizure risk, and the combination appears in essentially every serious contraindication list. People on lithium for bipolar disorder are excluded twice over — the diagnosis and the drug.
SSRIs and other serotonergics occupy the gray zone: rarely acutely dangerous with classic psychedelics (the MDMA interaction picture is different and worse), but blunting, complicating, and — via the stop-meds-to-trip trap — a genuine psychological hazard. These are physician-territory decisions, not self-help territory.
Pregnancy and the Developing Context
Pregnancy is a contraindication across essentially all serious protocols — not because psychedelics are known teratogens (the data barely exist), but because the precautionary principle applies doubly when a developing nervous system is the exposure target, and because the acute psychological stress of a challenging experience is itself a fetal stressor. The same logic that places pregnancy off-limits for most psychiatric medication changes belongs here.
What "Absolute" Means — and Doesn't
A note on the ethics of the word. Contraindications are medical judgments about risk and capacity, not moral ones — and they sit in tension with a real and painful reality: the populations most excluded (people with severe mental illness, people with bipolar disorder, people in psychiatric crisis) are often those in the deepest suffering, and the psychedelic renaissance's promise was substantially about them. The honest resolution of the tension is what the field itself is doing: not lifting the exclusions for solo use, but building supervised clinical frameworks — screened, monitored, with medical support on site — that might eventually let some of these populations in safely. Exclusion from the living-room session is not exclusion from the future of the medicine. But for now, the exclusions are the exclusions, and a person in one of these categories who proceeds anyway is not a rebel against caution; they're the unblinded arm of an experiment no ethics board would approve.
The Practical Screen
For anyone considering a session, the self-screen takes twenty honest minutes: personal history of psychosis, mania, or severe psychiatric instability; first-degree family history of schizophrenia or psychotic disorders; bipolar diagnosis of any kind; lithium or MAOI use; cardiac disease or uncontrolled blood pressure; pregnancy. Any "yes" closes the solo session question. Some yeses — the cardiac ones especially — can be worked through with a physician; the psychosis-spectrum and bipolar ones close it entirely outside clinical research. Twenty minutes of honesty against a lifetime of consequences. It's the cheapest insurance in this entire series.
